Double Medical reports strong Q3 results, approves equity incentive plan

Double Medical Technology reported a strong third quarter for 2025, with Q3 revenue up 17.82% to 665,815,103.16 yuan and a 77.49% rise in net profit attributable to shareholders, reaching 180,387,474.59 yuan. The company's year-to-date revenue climbed 22.69% to 1,876,254,824.66 yuan, with year-to-date net profit attributable to shareholders up 77.03% to 424,646,236.99 yuan. The board also approved the use of up to 250m yuan in idle self-owned funds for wealth management products.

The company's 2024 stock option incentive plan's first exercise period has met its conditions, allowing 643 eligible beneficiaries to exercise 2,155,900 shares at 23.39 yuan per share, representing 0.52% of the company's total share capital. This follows the board's review and approval, confirming that the company and individual performance targets were achieved.

Simultaneously, the board approved the cancellation of 3,493,000 shares of stock options from 97 beneficiaries who are no longer eligible due to departure or failure to meet performance targets. Additionally, amendments to the company's articles of association and various governance policies were approved, aligning with updated legal and regulatory requirements.